.jpg)
.png)
I would like to thank everyone who supported the Foundation of the National Lipid Association in 2018 by volunteering to work on our patient resource initiatives or awareness campaigns, attending a fundraiser, purchasing a Lipids Are My Life shirt at an NLA conference, speaking with your colleagues and patients about the Foundation or making a donation.
Article By:
President, Foundation of the National Lipid Association
Associate Professor of Medicine
Washington University School of Medicine
St. Louis, MO
Diplomate, American Board of Clinical Lipidology
Q: Could you tell us about what drew you to preventive cardiology?
Article By:
PhD Candidate
University of California-Irvine
Irvine, CA
Introduction
Article By:
Nutrition/Wellness Coach, Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID
Director, Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID
Director of Nutrition
Preventive Cardiology Program
Associate Clinical Professor of Medicine (Cardiology)
University of California Irvine
Irivine, CA
This year promises to be an important turning point for the Pacific Lipid Association (PLA). Our goal is to reinvigorate our membership through greater opportunities to serve the PLA and National Lipid Association (NLA). This can only be done by improving member communication and engaging our membership in activities that are both personally rewarding and promote the mission and goals of the PLA/NLA.
Article By:
President-Elect, Pacific Lipid Association
Associate Professor,
Pharmacy Practice and Administration
Western University of Health Sciences,
College of Pharmacy
Pomona, CA
Treasurer, Pacific Lipid Association
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
President, Pacific Lipid Association
Professor and Director, Heart Disease
Prevention Program
Division of Cardiology, University of California
Irvine, CA
Secretary, Pacific Lipid Association
Clinical Associate Professor/Director
Wellness Center, Kasiska Division of Health Sciences
Idaho State University
Pocatello, ID
Past President, Pacific Lipid Association
Private Practice: Endocrinology, Diabetes, Metabolism,
Internal Medicine
Medical Director and Principal Investigator
Metabolic Institute of America
Tarzana, CA
CASE STUDY
This case has unanswered questions but shows how a cardiologist and nurse practitioner who became certified lipid specialists create a team approach for their patient.
MS. TAYLOR AND DR. GREENFIELD:
Article By:
University of California-Irvine Medical Center
California Heart Associates
Fountain Valley, CA
Diplomate, American Board of Clinical Lipidology
Acute Care NP - Cardiology
MemorialCare Heart and Vascular Institute
Orange Coast Medical Center
Fountain Valley, CA
Inflammation is a dynamic process with many interconnected signaling pathways involving multiple classes of cells by which the human body responds to pathogen exposure and/or tissue damage, playing a central role in all stages of atherosclerosis. (1) Cholesterol crystals directly activate nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome and interleukin 1 beta (IL-1β) production.
Article By:
Department of Family Medicine
Oregon Health and Sciences University
Portland, OR
Diplomate, American Board of Clinical Lipidology
Along with lipid accumulation, inflammation plays a key role in the development of atherosclerosis.(1) Perhaps 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) inhibitors (statins) are effective in the prevention of atherosclerotic cardiovascular disease (ASCVD) because they significantly decrease low-density lipoprotein (LDL) particles and inflammation.
Article By:
Associate Professor, Pharmacy Practice and Administration
Western University of Health Sciences, College of Pharmacy
Pomona, CA
Atherosclerosis is widely recognized as a chronic inflammatory disorder. Therapies with anti-inflammatory effects in patients with an increased inflammatory status can reduce cardiovascular events, as the CANTOS study showed.(1) Inflammatory markers are an essential tool for evaluating a patient’s inflammatory state. The question is: which biomarker is best?
Article By:
Director, Advance Lipid Management Program
Tyler Heart Institute, Community Hospital of
Monterey Peninsula
Monterey, CA
Diplomate, American Board of Clinical Lipidology
Differentiating Biological Targets for Cardiovascular Risk Reduction from Risk Assessment Tools
Cardiovascular disease (CVD) remains the leading cause of mortality across the globe. The cornerstones of CVD prevention and treatment are accurate risk assessment — such that the intensity of preventive treatment matches the magnitude of absolute risk — and targeting biological markers that are known to mediate CV risk, respectively.
Article By:
Katz Preventive Cardiology Fellow
Division of Cardiology
Department of Medicine
Emory University School of Medicine
Atlanta, GA
Professor
Division of Cardiology
Department of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, TX
Introduction
Article By:
Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Department of Family Medicine
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology
Center for Preventive Cardiology,
Knight Cardiovascular Institute
Oregon Health and Science University
Portland, OR
Diplomate, American Board of Clinical Lipidology